The US Food and Drug Administration (FDA) has granted approval for Abbott’s Volt PFA System, expanding treatment options for patients with atrial fibrillation (AFib). The approval follows earlier CE ...

Approximately 12 million people in the United States over the age of 65 have AFib, a number expected to double over the next 20 years. FDA approval for the Volt PFA System was secured based on strong ...

Abbott ABT recently announced CE Mark approval for the Volt Pulsed Field Ablation (“PFA”) system to treat patients battling atrial fibrillation (AFib). The development came earlier than expected, ...

Enrollment completed ahead of schedule in the global IDE for Abbott (ABT)'s Volt™ PFA System Global FOCALFLEX trial now underway for Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ Advisor™ ...

Abbott (ABT)'s Volt™ PFA System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses high energy ...

Abbott Laboratories ABT recently received FDA approval for its Volt PFA System to treat patients battling atrial fibrillation (AFib). The company is expected to begin commercial PFA cases in the ...

Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month results of the Volt CE ...